{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:10:02Z","timestamp":1792692602311,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.leukres.2023.107042","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T15:59:45Z","timestamp":1676390385000},"page":"107042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Incidence of second primary malignancies in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma patients in England"],"prefix":"10.1016","volume":"127","author":[{"given":"Montserrat","family":"Miret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9602-4474","authenticated-orcid":false,"given":"Amanda","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Hindocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Cirneanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lymperopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuil","family":"Markov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kizito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando Emanuele","family":"Vegni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2023.107042_bib1","article-title":"Epidemiology of non-hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci. (Basel)"},{"issue":"10091","key":"10.1016\/j.leukres.2023.107042_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2023.107042_bib3","unstructured":"American Cancer Society, Treating B-Cell Non-Hodgkin Lymphoma, https:\/\/www.cancer.org\/cancer\/non-hodgkin-lymphoma\/treating\/b-cell-lymphoma.html. 2020. (Accessed 16 June 2022)."},{"key":"10.1016\/j.leukres.2023.107042_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CMAR.S34273","article-title":"Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies","volume":"5","author":"Chao","year":"2013","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.leukres.2023.107042_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/2278-330X.126531","article-title":"Management of relapsed-refractory diffuse large B cell lymphoma","volume":"3","author":"Raut","year":"2014","journal-title":"South Asian J. Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2023.107042_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107042_bib7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2023.107042_bib8","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107042_bib9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/cas.13239","article-title":"Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"108","author":"Makita","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.leukres.2023.107042_bib10","unstructured":"U.S. Food and Drug Administration, FDA approves axicabtagene ciloleucel for large B-cell lymphoma. Approved drugs. U.S. Food and Drug Administration, https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm581296.htm. 2018. (Accessed 16 August 2022)."},{"issue":"1","key":"10.1016\/j.leukres.2023.107042_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"26","key":"10.1016\/j.leukres.2023.107042_bib12","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.leukres.2023.107042_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107042_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.14638","article-title":"Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era","volume":"178","author":"Tao","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2023.107042_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2017.06.028","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a united states population-based study","volume":"17","author":"Giri","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.leukres.2023.107042_bib16","first-page":"3437","article-title":"Second primary malignancies in mantle cell lymphoma: a US population-based study","volume":"35","author":"Shah","year":"2015","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.leukres.2023.107042_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26363","article-title":"Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia","volume":"96","author":"F\u00fcrstenau","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107042_bib18","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1002\/cam4.849","article-title":"National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data","volume":"5","author":"Lenartova","year":"2016","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.leukres.2023.107042_bib19","first-page":"1262","article-title":"Increasing Incidence of B-cell non-hodgkin lymphoma and occurrence of second primary malignancies in South Korea: 10-year follow-up using the korean national health information database","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat."},{"issue":"3","key":"10.1016\/j.leukres.2023.107042_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/10428190902756578","article-title":"Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"50","author":"Seshadri","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.leukres.2023.107042_bib21","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2007.15.4773","article-title":"Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity","volume":"26","author":"Hoppe","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107042_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.14731","article-title":"A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results","volume":"178","author":"Srour","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107042_bib23","first-page":"1155","article-title":"Comparing findings from a friends of cancer research exploratory analysis of real-world end points with the cancer analysis system in England","volume":"5","author":"Horvat","year":"2021","journal-title":"JCO Clin. Cancer Inf."},{"key":"10.1016\/j.leukres.2023.107042_bib24","doi-asserted-by":"crossref","first-page":"v616","DOI":"10.1093\/annonc\/mdz260.023","article-title":"1501P - Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: a REAL-oncology analysis from the I-O Optimise initiative","volume":"30","author":"Snee","year":"2019","journal-title":"Ann. Oncol."},{"issue":"10, Supplement","key":"10.1016\/j.leukres.2023.107042_bib25","doi-asserted-by":"crossref","first-page":"S700","DOI":"10.1016\/j.jtho.2018.08.1145","article-title":"P2.01-91 treatment patterns in patients with stage IIIB-IV NSCLC in clinical practice: retrospective analysis of a UK trust database","volume":"13","author":"Snee","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.leukres.2023.107042_bib26","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/annonc\/mdz070.003","article-title":"45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB\u2013IV NSCLC in Portugal: an IPO-PORTO database analysis from the I-O optimise initiative","volume":"30","author":"Soares","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2023.107042_bib27","doi-asserted-by":"crossref","first-page":"viii537","DOI":"10.1093\/annonc\/mdy292.105","article-title":"1484P - Treatment patterns in patients (pts) with stage IIIB-IV non-small cell lung cancer (NSCLC) in Sweden: the SCAN-LEAF study","volume":"29","author":"Ekman","year":"2018","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2023.107042_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237509","article-title":"Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma","volume":"15","author":"Tsutsu\u00e9","year":"2020","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.leukres.2023.107042_bib29","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2217\/fon-2020-1041","article-title":"Defining treatment regimens and lines of therapy using real-world data in oncology","volume":"17","author":"Hess","year":"2021","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107042_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz076","article-title":"Data resource profile: national cancer registration dataset in England","volume":"49","author":"Henson","year":"2020","journal-title":"Int J. Epidemiol."},{"key":"10.1016\/j.leukres.2023.107042_bib31","unstructured":"NHS England, SACT Systemic Anti-Cancer Therapy Dataset, http:\/\/www.chemodataset.nhs.uk\/home. 2022. (Accessed 16 June 2022)."},{"key":"10.1016\/j.leukres.2023.107042_bib32","unstructured":"National Cancer Research and Analysis Service, National Radiotherapy Dataset (RTDS), http:\/\/www.ncin.org.uk\/collecting_and_using_data\/rtds. 2022. (Accessed 5 August 2022)."},{"key":"10.1016\/j.leukres.2023.107042_bib33","unstructured":"NHS Digital, Primary Care Mortality Database, https:\/\/digital.nhs.uk\/services\/primary-care-mortality-database. 2022. (Accessed 5 August 2022)."},{"key":"10.1016\/j.leukres.2023.107042_bib34","unstructured":"R. CoreTeam, R Foundation for Statistical Computing, Vienna, Austria, R: A language and environment for statistical computing, https:\/\/www.R-project.org\/. 2022. (Accessed 16 June 2022)."},{"issue":"13","key":"10.1016\/j.leukres.2023.107042_bib35","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2019030924","article-title":"Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes","volume":"3","author":"Herr","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2023.107042_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2019.100502","article-title":"Second primary malignancy in diffuse large B-cell lymphoma patients: a SEER database analysis","volume":"44","author":"Jiang","year":"2020","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.leukres.2023.107042_bib37","unstructured":"Cancer Research UK, All Cancers Excluding Non-Melanoma Skin Cancer (C00-C97 Excl. C44): 2016\u20132018, https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fwww.cancerresearchuk.org%2Fsites%2Fdefault%2Ffiles%2Fcancer-stat%2Fcases_crude_mf_allcancer_i18%2Fcases_crude_mf_allcancer_i18.xlsx&wdOrigin=BROWSELINK. (Accessed 12 November 2022)."},{"key":"10.1016\/j.leukres.2023.107042_bib38","unstructured":"Cancer Research UK, Non-Melanoma Skin Cancer (C44): 2016\u20132018, https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fwww.cancerresearchuk.org%2Fsites%2Fdefault%2Ffiles%2Fcancer-stat%2Fcases_crude_mf_nonmelanomaskin_i18%2Fcases_crude_mf_nonmelanomaskin_i18.xlsx&wdOrigin=BROWSELINK. (Accessed 12 November 2022)."},{"issue":"6","key":"10.1016\/j.leukres.2023.107042_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.leukres.2023.107042_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.14740\/jh890","article-title":"Treatment outcomes and survival patterns of asian patients with relapsed\/refractory mantle cell lymphoma","volume":"10","author":"Tan","year":"2020","journal-title":"J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107042_bib41","first-page":"110","article-title":"The treatment of relapsed refractory chronic lymphocytic leukemia, Hematology 2010","author":"Brown","year":"2011","journal-title":"Am. Soc. Hematol. Educ. Program Book 2011"},{"issue":"14","key":"10.1016\/j.leukres.2023.107042_bib42","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","article-title":"How I treat early-relapsing follicular lymphoma","volume":"133","author":"Casulo","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2023.107042_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/asheducation-2018.1.189","article-title":"Sequencing of therapies in relapsed follicular lymphoma","volume":"2018","author":"Nastoupil","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"1","key":"10.1016\/j.leukres.2023.107042_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.2021.278755","article-title":"Marginal zone lymphoma: present status and future perspectives","volume":"107","author":"Cheah","year":"2022","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.leukres.2023.107042_bib45","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107042_bib46","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/CMAR.S133291","article-title":"Management of relapsed\/refractory marginal zone lymphoma: focus on ibrutinib","volume":"10","author":"Denlinger","year":"2018","journal-title":"Cancer Manag Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:36Z","timestamp":1758935016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":46,"alternative-id":["S0145212623000279"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107042","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of second primary malignancies in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma patients in England","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107042"}}